PHARMACEUTICAL COMPOSITION CONTAINING A CYSTEINE PROTEASE INHIBITOR FOR PROPHYLAXIS AND THERAPY OF BRAIN TISSUE IMPAIRMENT
    12.
    发明公开
    PHARMACEUTICAL COMPOSITION CONTAINING A CYSTEINE PROTEASE INHIBITOR FOR PROPHYLAXIS AND THERAPY OF BRAIN TISSUE IMPAIRMENT 有权
    半胱氨酸抑制剂用于制备药物VORGBEUGUNG和治疗GEHIRNGEWEBEZERRÜTUNG而导致高血压脑病或ENCEPHALOTHLIPSIS使用

    公开(公告)号:EP1064021A1

    公开(公告)日:2001-01-03

    申请号:EP99909212.5

    申请日:1999-03-17

    IPC分类号: A61K38/55

    CPC分类号: A61K31/18 A61K31/16 A61K38/05

    摘要: A pharmaceutical composition for the prophylaxis and therapy of brain tissue impairment, which contains, as an active ingredient, a compound of formula (I) wherein R1 represents an alkyl group having 1-4 carbon atoms or an aryl group having 6-10 carbon atoms which is optionally substituted; R?2 and R3¿ may be the same or different and each represents hydrogen or an alkyl group having 1-4 carbon atoms or R?2 and R3¿ may jointly form a ring having 3-7 carbon atoms; and R4 represents a lower alkyl group which is optionally substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof.

    摘要翻译: 用于预防和脑组织损伤,其中含有作为活性成分的治疗的药物组合物,下述式(I)具有1至4个碳原子或芳基具有6-10烷基的R1 worin darstellt的化合物 碳原子的所有其任选substituiertem; R2和R3可以相同或不同,且各自为氢或darstellt具有1-4个碳原子或R2和R3可以共同形成具有3-7个碳原子的环烷基的; 和R4 darstellt低级烷基所有这些任选地被芳基,环烷基或芳族杂环残基,或其药学上可接受的盐substituiertem。

    PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY
    13.
    发明公开
    PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY 有权
    用于预防的药物组合物及其与细胞背景眼相关疾病病证治疗

    公开(公告)号:EP1058553A2

    公开(公告)日:2000-12-13

    申请号:EP99907856.1

    申请日:1999-03-03

    IPC分类号: A61K31/63

    CPC分类号: A61K38/00 A61K31/18

    摘要: A pharmaceutical composition for the prophylaxis and therapy of a disease arising from ocular fundus tissue cytopathy such as retinochoroidal disease, glaucoma, and posterior complication arising form photocoagulation, which contains, as an active ingredient, a compound of formula (I) wherein R1 represents an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 10 carbon atoms which is optionally substituted; R?2 and R3¿ may be the same or different and each represents hydrogen or an alkyl group having 1 to 4 carbon atoms or R?2 and R3¿ may jointly form a ring having 3 to 7 carbon atoms; and R4 represents a lower alkyl group which is optionally substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof.

    AGENT FOR REPAIRING CORNEAL PERCEPTION
    17.
    发明公开
    AGENT FOR REPAIRING CORNEAL PERCEPTION 有权
    2-氯-6,7-二甲氧基 - N-5 [5-(1)H-吲唑基]喹唑啉-4-胺,N-(1-苄基-4-哌啶基)-1H-吲唑-5-胺二盐酸盐, 4- [2-(2,3,4,5,6-五氟苯基)丙烯酰基]肉桂酸和法舒地尔盐酸盐在角膜感知的恢复中使用。

    公开(公告)号:EP1616577A1

    公开(公告)日:2006-01-18

    申请号:EP04728020.1

    申请日:2004-04-16

    摘要: The present invention provides a novel pharmaceutical agent for recovering corneal sensitivity after corneal surgery and improving symptoms of dry eye. This pharmaceutical agent is useful for improving decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as post-cataract operation, post-LASIK operation, post-PRK operation, postkeratoplasty operation, neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like, since it contains a Rho protein inhibitor.

    摘要翻译: 本发明提供了用于角膜手术后恢复角膜敏感性和改进干眼症状的新的药剂。 此药剂是用于提高角膜敏感性降低和角膜神经变性有关的干眼病有用:如白内障手术后,后LASIK手术,后PRK手术,postkeratoplasty手术,神经麻痹性角膜病,角膜溃疡,糖尿病性角膜病等,由于 它含有的Rho蛋白抑制剂。

    REMEDY FOR CORNEAL FAILURE
    18.
    发明公开
    REMEDY FOR CORNEAL FAILURE 审中-公开
    HEILMITTELFÜRHORNHAUTDEFEKT

    公开(公告)号:EP1566184A1

    公开(公告)日:2005-08-24

    申请号:EP03758790.4

    申请日:2003-10-22

    CPC分类号: A61K38/31 A61K31/00

    摘要: The present invention provides a new type of pharmaceutical agent that recovers corneal sensitivity after corneal surgery or improves the condition of dry eye. Application of a somatostatin receptor agonist is expected to provide an improvement effect on decreased corneal sensitivity after cataract surgery or LASIK surgery, decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like.

    摘要翻译: 本发明提供了在角膜手术后恢复角膜敏感性或改善干眼症状的新型药剂。 预期生长抑素受体激动剂的应用对于白内障手术或LASIK手术后的角膜敏感性降低,与角膜神经变性如神经麻痹性角膜病,角膜溃疡,糖尿病性角膜病等相关的角膜敏感性和干性眼睛的降低有改善作用。